Tagged Articles

Taxotere 76 articles

Drug company accused of falsely marketing cancer drug Taxotere now faces lawsuits

Chemotherapy drug Taxotere is under fire not only for allegedly causing permanent hair loss, but also because drugmaker Sanofi SA allegedly falsely marketed the drug’s “superior efficacy” compared to similar competing drugs. According to Law360, one suit against the pharmaceutical company alleges that the company based its marketing on self-sponsored clinical trials while other studies were finding that competing drugs were more effective in certain patients. “Contrary to defendants’ claims of superior efficacy, post-market surveillance has shown that the more potent and more toxic Taxotere does not, in fact, offer increased efficacy or benefits over other taxanes, as defendants have ... Read More

Studies identify drugs that can reverse hair loss

Scientists are working to find treatments for people who are suffering physically and emotionally from hair loss. CNN reports about a recent study that has had success for alopecia patients. Sixty-five participants of a recent study conducted at Stanford, Yale and Columbia took rheumatoid arthritis medication, Xeljanz. More than half of the study subjects saw hair regrowth and a third recovered more than 50 percent of their lost hair. One man CNN features grew his hair back within seven months and expressed great satisfaction with the results. “It affects every part of your life. I got very depressed, and it was ... Read More

Lawsuits against chemotherapy drug Taxotere consolidated in Louisiana

Thirty-three cases that had been filed federally across the U.S. against pharmaceutical company Sanofi SA were consolidated this month into a multidistrict litigation (MDL) in Louisiana district court, according to Law360. The drug maker is accused of marketing its chemotherapy drug Taxotere as superior to similar competing drugs, while concealing that the drug caused permanent hair loss. Law360 quotes from one of the suits filed by Ami Dodson in California saying that Sonafi SA began misrepresenting the safety and effectiveness of Taxotere as early as 1996, the year that the drug was approved for use by the Food and Drug ... Read More

Lawsuit claims breast cancer drug Taxotere causes permanent baldness

A California woman is suing the makers of the breast cancer treatment Taxotere claiming the medication was more toxic than competitor drugs and could cause permanent hair loss, yet the drug company withheld this information in order to grow profits. Ami Dodson’s lawsuit, which names Sanofi, Aventis Pharma SA and Sanofi-Aventis US LLC, alleges the companies preyed on “one of the most vulnerable groups of individuals at the most difficult times of their lives” during which they “obtained billions of dollars in increased revenues at the expense of unwary cancer victims simply hoping to survive their condition and return to ... Read More

FDA warns that chemotherapy drug may cause patients to feel drunk

The intravenous chemotherapy drug docetaxel contains ethanol, also known as alcohol, which can cause patients to feel intoxicated, or drunk, during and after treatment, the Food and Drug Administration (FDA) warned in a safety communication. The agency is ordering all docetaxel drug products to add a warning to their safety labels regarding this possible side effect. Docetaxel is a prescription chemotherapy drug used to treat various types of cancer including breast, prostate, stomach, head and neck, and non-small-cell lung cancers. It is known by the brand names Taxotere and Docefrez. Known as a taxane, the drug works by interfering with microtubules, ... Read More

New breast cancer drug shows promise in clinical trials

A chemotherapy drug discontinued in the 1980s because it was too lethal to patients is showing promise when combined with another drug in the treatment of breast cancer. The combination drug pairs the cancer-retarding abilities of Roche Holding AG’s Herceptin with the chemotherapy drug maytansine into one drug called T-DM1.  In a study of 137 women with metastatic breast cancer, the women who had received T-DM1 had a 41 percent reduction in risk of their cancer worsening compared to women who used the more traditional Herceptin plus Taxotere. Breast cancer is the biggest cancer killer among women, with about 1.4 new ... Read More